- Home
- SA vs ELVN Comparison
SA vs ELVN Comparison
Compare SA & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SA
- ELVN
- Stock Information
- Founded
- SA 1979
- ELVN 2016
- Country
- SA Canada
- ELVN United States
- Employees
- SA N/A
- ELVN N/A
- Industry
- SA Precious Metals
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- SA Basic Materials
- ELVN Health Care
- Exchange
- SA Nasdaq
- ELVN Nasdaq
- Market Cap
- SA 1.0B
- ELVN 1.0B
- IPO Year
- SA N/A
- ELVN 2020
- Fundamental
- Price
- SA $12.58
- ELVN $21.60
- Analyst Decision
- SA
- ELVN Strong Buy
- Analyst Count
- SA 0
- ELVN 5
- Target Price
- SA N/A
- ELVN $37.80
- AVG Volume (30 Days)
- SA 577.1K
- ELVN 269.1K
- Earning Date
- SA 03-28-2025
- ELVN 03-13-2025
- Dividend Yield
- SA N/A
- ELVN N/A
- EPS Growth
- SA N/A
- ELVN N/A
- EPS
- SA N/A
- ELVN N/A
- Revenue
- SA N/A
- ELVN N/A
- Revenue This Year
- SA N/A
- ELVN N/A
- Revenue Next Year
- SA N/A
- ELVN N/A
- P/E Ratio
- SA N/A
- ELVN N/A
- Revenue Growth
- SA N/A
- ELVN N/A
- 52 Week Low
- SA $9.31
- ELVN $10.90
- 52 Week High
- SA $20.55
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- SA 53.83
- ELVN 47.03
- Support Level
- SA $11.57
- ELVN $20.40
- Resistance Level
- SA $12.78
- ELVN $22.42
- Average True Range (ATR)
- SA 0.43
- ELVN 1.25
- MACD
- SA 0.14
- ELVN 0.06
- Stochastic Oscillator
- SA 79.34
- ELVN 59.59
About SA Seabridge Gold Inc. (Canada)
Seabridge Gold Inc is a development stage company involved in the exploration, and development of gold properties sited in North America. The company's principal projects include the Kerr-Sulphurets-Mitchell property located in British Columbia, the Courageous Lake property located in the Northwest Territories, and Iksut Property located in northwestern British Columbia, and the 3 Aces Project in southeast Yukon. The company has various other mineral resource projects throughout North America.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.